Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irbesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 6/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015144 | 0.95 | AGTR1 (0.90) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL30256694 | 0.92 | AGTR1 (0.84) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21083866 | 0.92 | AGTR1 (0.84) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL16482976 | 0.91 | AGTR1 (0.82) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21125435 | 0.90 | AGTR1 (0.81) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21083864 | 0.90 | AGTR1 (0.81) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21083650 | 0.89 | AGTR1 (0.80) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL16691909 | 0.88 | AGTR1 (0.79) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21083838 | 0.88 | AGTR1 (0.79) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL21125637 | 0.88 | AGTR1 (0.79) | AGTR1LTB4R2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| EP-2252327-A2 | METHODS OF TREATING COPD | Schering Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-2194050-A1 | A new process for the preparation of irbesartan | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2010-06-09 | — | — | EP | claimed |
| WO-2009073683-A2 | METHODS OF TREATING COPD | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| EP-1998788-A2 | COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS | Tristrata Inc. (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2008140460-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008140459-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2007103687-A2 | COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS | TRISTRATA, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| CN-101011393-A | Irbesartan gastric retention sustained-release pharmaceutical composition | GUANGZHOU BEII S MEDICINE CO L (CN) | 2007-08-08 | — | — | CN | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4215194-B1 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | DIMERIX BIOSCIENCE PTY LTD (AU) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1198451-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001028548-A1 | TREATMENT OF HEART DISEASE WITH COX-2 INHIBITORS | TEXAS HEART INSTITUTE (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | AGTR1 846/4885LTB4R2 478/4885ABCC3 3846/4885 |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | AGTR1 1128/4885LTB4R2 589/4885ABCC3 2462/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | AGTR1 4851/4885LTB4R2 4357/4885ABCC3 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.